Several tumor phenotypes have been identified to date (luminal A, luminal B, HER2+, and triple-negative), depending on the putative molecular targets such as estrogen receptors (ER), progesterone receptors (PR), the human epidermal growth factor 2 receptor (HER2) and Ki-67 level. This evidence concerns the gene ERBB2 and neoplasm.